Merck's Q1 sales surpassed expectations, driven by strong demand for Keytruda. Despite acquisition-related losses, investors ...

What is Keytruda and how does it work? Experts explain the cancer immunotherapy as a global investigation raises concerns ...

On the heels of several big buys, Merck still has eyes for M&A—particularly in the oncology, immunology and cardiometabolic ...

A game changer in cancer treatment, Keytruda, works by harnessing the body’s immune system to attack cancer cells. While its ...

Merck is scheduled to report first-quarter earnings on April 30, during market hours, with analysts expecting a strong ...

First approved by the US FDA in 2014 for advanced skin cancer, Keytruda is now used globally for certain lung cancers, cervical cancer, renal cell cancer and aggressive breast cancer, among others.

Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.

Merck & Co reported a loss in Q1 due to acquisition charges despite increased cancer and respiratory drugs sales. Revenue was $16.3 billion, beating estimates. Keytruda sales rose 12% to $8 billion, ...